All
Rituximab Biosimilar Meets Endpoint in Phase III Follicular Lymphoma Trial
January 25th 2018Pfizer has announced that PF-05280586, a biosimilar for rituximab, has delivered positive top-line results, meeting its primary endpoint for overall response rate in the in the phase III REFLECTIONS B3281006 trial for patients with follicular lymphoma.
Napabucasin/Pembrolizumab Combo Shows Early Signs of Efficacy in mCRC
January 25th 2018According to results reported at the 2018 Gastrointestinal Cancers Symposium, early signs of efficacy were seen with the investigational oral cancer stem cell pathway inhibitor napabucasin (BBI608) combined with the PD-1 inhibitor pembrolizumab (Keytruda) in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.
Nivolumab Produces Durable Responses Alone and With Ipilimumab in MSI-H/dMMR mCRC
January 24th 2018According to 2 analyses presented at the 2018 Gastrointestinal Cancers Symposium, data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.
Hicks Named Chief of Gynecologic Oncology at Jersey Shore University Medical Center
January 24th 2018Hackensack Meridian Health has announced that Verda J. Hicks, MD, FACS, FACOG, will serve as its chief of Gynecologic Oncology at Jersey Shore University Medical Center. She will be joined by associates James R. Bosscher, MD, and Karim ElSahwi, MD, to facilitate promising experience and care to the Monmouth, Ocean, and Middlesex counties.
Kathy Albain Named First Huizenga Family Endowed Chair at Loyola University Chicago
January 24th 2018Kathy S. Albain, MD, has been named the inaugural Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine. Funded by Heidi Huizenga, one of Albain’s beholden patients, her husband, and her family, the endowed chair recognizes Albain’s notable contributions as a physician, research, teacher and mentor.
Dose Escalating Regorafenib Superior to Standard Dose in CRC, Study Finds
January 23rd 2018According to findings reported during the 2018 Gastrointestinal Cancers Symposium, a weekly dose-escalation strategy of regorafenib (Stivarga) beginning at 80 mg and ending at 160 mg was found to be superior than the previously standard starting dose of 160 mg in patients with metastatic colorectal cancer.
Survival Improved with Tumor-Treating Fields in Glioblastoma
January 23rd 2018Progression-free survival and overall survival were improved for patients with glioblastoma by adding tumor-treating fields to temozolomide (Temodar), according to a final analysis of results from the EF-14 trial.
Nab-Paclitaxel/Gemcitabine Induces Encouraging Responses in Locally Advanced Pancreatic Cancer
January 22nd 2018In patients with newly diagnosed locally advanced pancreatic cancer, induction treatment with nab-paclitaxel (Abraxane) plus gemcitabine induced an overall disease control rate of 77.6%, according to updated findings from the phase II LAPACT trial presented at the 2018 Gastrointestinal Cancers Symposium.
Frontline Daratumumab Granted FDA's Priority Review for Multiple Myeloma
January 22nd 2018Based on findings from the ALCYONE study, which were published in the <em>New England Journal of Medicine</em> and presented at the 2017 ASH Annual Meeting,<sup> </sup>the FDA has granted a priority review designation to daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Expert Discusses Promising Efficacy of Oral Azacitidine in High-Risk Lymphoma
January 22nd 2018Peter Martin, MD, discusses a phase I, open-label, multicenter trial of oral azacitidine (Vidaza) plus R-CHOP in people with high-risk, previously untreated DLBCL, grade 3B follicular lymphoma, or transformed lymphoma.
Avelumab Activity in Platinum-Refractory Bladder Cancer Confirmed in Published Results
January 19th 2018According to results from the phase I JAVELIN Solid Tumor study recently published in the Lancet Oncology, the PD-L1 inhibitor avelumab (Bavencio) induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.
Kundranda Discusses Options for Therapy in 2 HCC Patient Cases
January 19th 2018Madappa Kundranda, MD, PhD, recently discussed the cases of 2 patients with hepatocellular carcinoma (HCC), and the treatment considerations and decisions he would make when treating these patients. Dr. Kundranda, Director of Gastrointestinal Oncology at Banner MD Anderson Cancer Center, Phoenix discussed these cases during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Trastuzumab Does Not Increase Cardiac Toxicity in HER2+ Breast Cancer, Study Finds
January 18th 2018According to long-term follow-up results from the National Surgical Adjuvant Breast and Bowel Project B-31 trial published in the <em>Journal of Clinical Oncology</em>,<em> </em>trastuzumab (Herceptin) did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.
Anthony Tolcher Joins Texas Oncology to Expand San Antonio Research Program
January 18th 2018Internationally recognized cancer researcher Anthony Tolcher, MD, has joined Texas Oncology’s San Antonio Medical Center, where he will help develop and expand Texas Oncology’s current comprehensive research and clinical trials program.
FDA Grants Approval to Carfilzomib Label Update in Myeloma
January 18th 2018The FDA has issued its approval for overall survival data from the phase III ENDEAVOR trial to be added to the carfilzomib (Kyprolis) label for use in patients with relapsed or refractory multiple myeloma.
Blood-Based Liquid Biopsy Demonstrates 88% Accuracy in Detecting Colorectal Cancers Early
January 17th 2018A novel circulating tumor cell assay has demonstrated a high accuracy of up to 88% for detecting early-stage colorectal cancer, according to the results of a prospective study from Taiwan released ahead of a presentation at the 2018 Gastrointestinal Cancers Symposium in San Francisco, California. The study marks the first to show a high sensitivity for detecting precancerous lesions, as prior studies tended to identify later-stage CRCs.
Expert Discusses Treatment Options for Patients with MCL Based on 2 Case Scenarios
January 17th 2018Mitchell R. Smith, MD, PhD, recently shared both the more and less intensive treatment considerations he makes when treating patients with MCL and the major factors that influence them. Smith explained such considerations based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.
Tisagenlecleucel Granted Priority Review by FDA for DLBCL
January 17th 2018Based on results of the phase II JULIET study, a supplemental biologics license application for the CAR T-cell therapy tisagenlecleucel (Kymriah) has been granted a priority review by the FDA as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for or relapse after autologous stem cell transplant.
Beckerle Awarded NCI Award for Research on Genetics of Cancer
January 17th 2018Mary C. Beckerle, PhD, has been awarded the Alfred G. Knudson Award in Cancer Genetics by the National Cancer Institute (NCI). She received her award at the NCI’s Maryland headquarters before delivering a lecture on tumor biology.
Arsenic Trioxide Approved by FDA for Promyelocytic Leukemia
January 17th 2018Arsenic trioxide (Trisenox) has been approved by the FDA in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or <em>PML-RARA</em> gene expression.
Neoadjuvant Chemoradiotherapy Does Not Improve HRQOL in Esophageal Cancer
January 16th 2018In results from the phase III CROSS trial reported in the <em>Journal of Clinical Oncology, </em>neoadjuvant chemoradiotherapy failed to lower postoperative health-related quality of life compared with surgery alone for patients with esophageal or junctional cancer.<br />
Frontline Immunochemotherapy Recommended in Advanced-Stage Follicular Lymphoma
January 16th 2018Long-term follow-up results of the FOLL05 trial confirm the efficacy of immunochemotherapy regimens for patients with previously untreated advanced-stage follicular lymphoma, according to findings of a post-hoc analysis recently published in the <em>Journal of Clinical Oncology </em>covering a median 7 years of follow-up.
Mark Israel Joins the Israel Cancer Research Fund as National Executive Director
January 16th 2018A nationally recognized leader in cancer research, Mark A. Israel, MD, has joined the Israel Cancer Research Fund as national executive director. The ICRF is the largest nonprofit organization dedicated exclusively to funding cancer research in Israel at present.
The Influence of Mutational Status in Intrahepatic Cholangiocarcinoma
January 15th 2018Jesper B. Andersen, MSc, PhD, discusses a study that shows using a single-gene dissection approach in patients with intrahepatic cholangiocarcinoma can characterize divergent cancer programs and drug vulnerabilities.
Afatinib Approval for Lung Cancer Expanded by FDA
January 15th 2018The frontline indication for afatinib (Gilotrif) has been expanded by the FDA to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon <em>EGFR</em> alterations in L861Q, G719X, and/or S768I.